학술논문

Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial
Document Type
article
Source
Clinical Infectious Diseases. 66(2)
Subject
Prevention
Clinical Trials and Supportive Activities
Clinical Research
Complementary and Integrative Health
Nutrition
Pediatric
6.1 Pharmaceuticals
Evaluation of treatments and therapeutic interventions
Adolescent
Anti-HIV Agents
Bone Density
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents
Cholecalciferol
Double-Blind Method
Female
HIV Infections
Humans
Male
Placebos
Spine
Tenofovir
Treatment Outcome
Young Adult
tenofovir disoproxil fumarate
vitamin D supplementation
bone mineral density
parathyroid hormone
HIV infection
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team
Biological Sciences
Medical and Health Sciences
Microbiology
Language
Abstract
BackgroundTenofovir disoproxil fumarate (TDF) decreases bone mineral density (BMD). We hypothesized that vitamin D3 (VITD3) would increase BMD in youth receiving TDF.MethodsThis was a randomized, double-blind, placebo-controlled trial of directly observed VITD3 vs placebo every 4 weeks for 48 weeks in youth aged 16-24 years with HIV, RNA load